Susan Hasty, Publisher
Table of Contents . . . November 7th, 2001
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Vaccine Weekly | Other Publications
HIV Vaccine - Early Cytotoxic T-Cell Responses May Be Key To Development
Smallpox - Study Will Try Smaller Vaccine Dose
Anthrax - New DNA-Based Vaccine Approach Protects Mice
HIV Vaccine - Clinical Trials Begin In Healthy Individuals At UC Davis
Skin Cancer - Tumor Vaccine Causes Regression, Reduces Metastasis In Incurable Melanoma
Vaccine Efficacy - Hepatitis B Vaccine Response Falls Short In Youth, Those With HIV
Anthrax - BioPort Is Trying To Get FDA Approval For Manufacturing Vaccine
Asthma - Phase II Study Of Humanized Anti-IL-4 Antibody Initiated
Bioterrorism - Avant Licenses Vaccine Technology To U.S. Department of Defense Contractor
Bioterrorism - Public Health Executive Explores Making Vaccines Available To Public
Cancer Vaccines - FDA Fast Tracks Antigenics' Oncophage For Kidney Cancer
Cervical Cancer - Genetically Engineered Vaccine Elicits Immune Response To Kill Tumor
Contracts - TherImmune Awarded $4.5 Million For HIV Vaccine Development Services
Drug Development - Avax Expects Clearance To Continue With Its Autologous Cell Vaccines
Dysentery - Antex To Continue DOD Grant Work On Gastrointestinal Vaccine
Functional Genomics - Viragen Reports On Avian Transgenic Project
Gastric Cancer - Amarillo Biosciences Receives Grant To Develop H. pylori Vaccine
Genital Herpes - Phase II Trial Results Of Therapeutic Vaccine Are Encouraging
HIV Complications - Cambridge Antibody Technology Announces Product Development Alliance With Merck
HIV Vaccine - Elispot Assay May Hasten Development Of African Vaccine
HIV Vaccine - Immunoglobulins From Resistant Sex Workers May Provide Protection
Influenza - Healthy People Urged To Postpone Immunization Until November
T-Cell Prolymphocytic Leukemia - Alemtuzumab Successful In Clinical Trial
Vector Development - Gene Vectors Might Be Next Best Thing For Vaccine Studies
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.